FULCRUM THERAPEUTICS, INC. (FULC) Free cash flow
- Free cash flow · 12 months (USD): Value $-66.14M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-66.14M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-65.78M − $365.00K ≈ $-66.14M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-65.78M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.77× | Operating cash flow / net income. Period ending 2026-06-30. $-65.78M ÷ $-85.00M ≈ 0.77× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -65.78M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 365.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -66.14M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -85.00M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-66.14M | (m) | $-65.78M | $365.00K | (m) | (m) | (m) | $-85.00M | (m) | (m) | (m) | 0.77× |
| 2026-03-31 | $-63.88M | (m) | $-63.56M | $322.00K | (m) | (m) | (m) | $-76.12M | (m) | (m) | (m) | 0.84× |
| 2025-12-31 | $-60.38M | (m) | $-60.06M | $314.00K | (m) | (m) | (m) | $-74.88M | (m) | (m) | (m) | 0.80× |
| 2025-09-30 | $-60.41M | (m) | $-60.03M | $386.00K | (m) | (m) | (m) | $-71.11M | (m) | (m) | (m) | 0.84× |
| 2025-06-30 | $-65.22M | (m) | $-64.91M | $315.00K | (m) | (m) | (m) | $-73.22M | (m) | (m) | (m) | 0.89× |
| 2025-03-31 | $7.56M | (m) | $7.81M | $250.00K | (m) | (m) | (m) | $-510.00K | (m) | (m) | (m) | -15.31× |
| 2024-12-31 | $-2.50M | (m) | $-2.22M | $278.00K | (m) | (m) | (m) | $-9.72M | (m) | (m) | (m) | 0.23× |
| 2024-09-30 | $-8.74M | (m) | $-8.62M | $124.00K | (m) | (m) | (m) | $-17.91M | (m) | (m) | (m) | 0.48× |
| 2024-06-30 | $-12.62M | (m) | $-12.45M | $170.00K | (m) | (m) | (m) | $-20.23M | (m) | (m) | (m) | 0.62× |
| 2024-03-31 | $-92.50M | (m) | $-92.13M | $365.00K | (m) | (m) | (m) | $-99.43M | (m) | (m) | (m) | 0.93× |
| 2023-12-31 | $-91.47M | (m) | $-90.97M | $508.00K | (m) | (m) | (m) | $-97.33M | (m) | (m) | (m) | 0.93× |
| 2023-09-30 | $-88.05M | (m) | $-87.50M | $547.00K | (m) | (m) | (m) | $-98.71M | (m) | (m) | (m) | 0.89× |
| 2023-06-30 | $-93.24M | (m) | $-92.48M | $765.00K | (m) | (m) | (m) | $-98.44M | (m) | (m) | (m) | 0.94× |
| 2023-03-31 | $-100.95M | (m) | $-99.06M | $1.89M | (m) | (m) | (m) | $-108.72M | (m) | (m) | (m) | 0.91× |
| 2022-12-31 | $-99.01M | (m) | $-97.05M | $1.96M | (m) | (m) | (m) | $-109.87M | (m) | (m) | (m) | 0.88× |
| 2022-09-30 | $-101.58M | (m) | $-99.21M | $2.37M | (m) | (m) | (m) | $-107.22M | (m) | (m) | (m) | 0.93× |
| 2022-06-30 | $-96.35M | (m) | $-93.90M | $2.45M | (m) | (m) | (m) | $-104.20M | (m) | (m) | (m) | 0.90× |
| 2022-03-31 | $-86.06M | (m) | $-84.36M | $1.70M | (m) | (m) | (m) | $-89.78M | (m) | (m) | (m) | 0.94× |
| 2021-12-31 | $-80.19M | (m) | $-78.48M | $1.71M | (m) | (m) | (m) | $-80.85M | (m) | (m) | (m) | 0.97× |
| 2021-09-30 | $-78.11M | (m) | $-76.45M | $1.67M | (m) | (m) | (m) | $-75.08M | (m) | (m) | (m) | 1.02× |
| 2021-06-30 | $-59.77M | (m) | $-58.38M | $1.39M | (m) | (m) | (m) | $-73.33M | (m) | (m) | (m) | 0.80× |
| 2021-03-31 | $-55.71M | (m) | $-54.68M | $1.04M | (m) | (m) | (m) | $-69.37M | (m) | (m) | (m) | 0.79× |
| 2020-12-31 | $-55.00M | (m) | $-53.66M | $1.34M | (m) | (m) | (m) | $-70.82M | (m) | (m) | (m) | 0.76× |
| 2020-09-30 | $-39.30M | (m) | $-38.32M | $978.00K | (m) | (m) | (m) | $-69.22M | (m) | (m) | (m) | 0.55× |
| 2020-06-30 | $-47.94M | (m) | $-46.84M | $1.10M | (m) | (m) | (m) | $-66.80M | (m) | (m) | (m) | 0.70× |
| 2020-03-31 | $-45.90M | (m) | $-44.79M | $1.11M | (m) | (m) | (m) | $-64.29M | (m) | (m) | (m) | 0.70× |
| 2019-12-31 | $-40.34M | (m) | $-39.48M | $853.00K | (m) | (m) | (m) | $-82.68M | (m) | (m) | (m) | 0.48× |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-62.49M | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-31.54M | (m) | $-22.56M | $8.98M | (m) | (m) | (m) | $-32.59M | (m) | (m) | (m) | 0.69× |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |